These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

266 related items for PubMed ID: 26701733

  • 1. Cytomegalovirus disease is associated with higher all-cause mortality after lung transplantation despite extended antiviral prophylaxis.
    Beam E, Lesnick T, Kremers W, Kennedy CC, Razonable RR.
    Clin Transplant; 2016 Mar; 30(3):270-8. PubMed ID: 26701733
    [Abstract] [Full Text] [Related]

  • 2. Risk factors, survival, and impact of prophylaxis length in cytomegalovirus-seropositive lung transplant recipients: A prospective, observational, multicenter study.
    Monforte V, Sintes H, López-Gallo C, Delgado M, Santos F, Zurbano F, Solé A, Gavaldá J, Borro JM, Redel-Montero J, Cifrian JM, Pastor A, Román A, Ussetti P.
    Transpl Infect Dis; 2017 Jun; 19(3):. PubMed ID: 28294487
    [Abstract] [Full Text] [Related]

  • 3. Valganciclovir prophylaxis versus preemptive therapy in cytomegalovirus-positive renal allograft recipients: 1-year results of a randomized clinical trial.
    Witzke O, Hauser IA, Bartels M, Wolf G, Wolters H, Nitschke M, VIPP Study Group.
    Transplantation; 2012 Jan 15; 93(1):61-8. PubMed ID: 22094954
    [Abstract] [Full Text] [Related]

  • 4. Lower incidence of CMV infection and acute rejections with valganciclovir prophylaxis in lung transplant recipients.
    Johansson I, Mårtensson G, Nyström U, Nasic S, Andersson R.
    BMC Infect Dis; 2013 Dec 10; 13():582. PubMed ID: 24325216
    [Abstract] [Full Text] [Related]

  • 5. Cytomegalovirus disease among donor-positive/recipient-negative lung transplant recipients in the era of valganciclovir prophylaxis.
    Mitsani D, Nguyen MH, Kwak EJ, Silveira FP, Vadnerkar A, Pilewski J, Crespo M, Toyoda Y, Bermudez C, Clancy CJ.
    J Heart Lung Transplant; 2010 Sep 10; 29(9):1014-20. PubMed ID: 20598582
    [Abstract] [Full Text] [Related]

  • 6. Cytomegalovirus disease and infection in lung transplant recipients in the setting of planned indefinite valganciclovir prophylaxis.
    Wiita AP, Roubinian N, Khan Y, Chin-Hong PV, Singer JP, Golden JA, Miller S.
    Transpl Infect Dis; 2012 Jun 10; 14(3):248-58. PubMed ID: 22385394
    [Abstract] [Full Text] [Related]

  • 7. Cytomegalovirus Immunoglobulin for Prophylaxis and Treatment of Cytomegalovirus Infection in the (Val)Ganciclovir Era: A Single-Center Experience.
    Lopez Garcia-Gallo C, García Fadul C, Laporta R, Portero F, Millan I, Ussetti P.
    Ann Transplant; 2015 Nov 05; 20():661-6. PubMed ID: 26537426
    [Abstract] [Full Text] [Related]

  • 8. Impact of donor and recipient cytomegalovirus serology on long-term survival of lung transplant recipients.
    Mabilangan C, Preiksaitis J, Cervera C, University of Alberta Cardiothoracic Transplant Group.
    Transpl Infect Dis; 2018 Oct 05; 20(5):e12964. PubMed ID: 29981174
    [Abstract] [Full Text] [Related]

  • 9. Cytomegalovirus infection in heart transplantation: A single center experience.
    Echenique IA, Angarone MP, Rich JD, Anderson AS, Stosor V.
    Transpl Infect Dis; 2018 Aug 05; 20(4):e12896. PubMed ID: 29602266
    [Abstract] [Full Text] [Related]

  • 10. Delayed-onset primary cytomegalovirus disease after liver transplantation.
    Arthurs SK, Eid AJ, Pedersen RA, Dierkhising RA, Kremers WK, Patel R, Razonable RR.
    Liver Transpl; 2007 Dec 05; 13(12):1703-9. PubMed ID: 18044717
    [Abstract] [Full Text] [Related]

  • 11. Multicenter evaluation of efficacy and safety of low-dose versus high-dose valganciclovir for prevention of cytomegalovirus disease in donor and recipient positive (D+/R+) renal transplant recipients.
    Heldenbrand S, Li C, Cross RP, DePiero KA, Dick TB, Ferguson K, Kim M, Newkirk E, Park JM, Sudaria-Kerr J, Tichy EM, Ueda KR, Weng R, Wisniewski J, Gabardi S.
    Transpl Infect Dis; 2016 Dec 05; 18(6):904-912. PubMed ID: 27639246
    [Abstract] [Full Text] [Related]

  • 12. Costs and outcomes of prolonged cytomegalovirus prophylaxis to cover the enhanced immunosuppression phase following lung transplantation.
    Gerbase MW, Dubois D, Rothmeier C, Spiliopoulos A, Wunderli W, Nicod LP.
    Chest; 1999 Nov 05; 116(5):1265-72. PubMed ID: 10559085
    [Abstract] [Full Text] [Related]

  • 13. Does valganciclovir hydrochloride (valcyte) provide effective prophylaxis against cytomegalovirus infection in liver transplant recipients?
    Jain A, Orloff M, Kashyap R, Lansing K, Betts R, Mohanka R, Menegus M, Ryan C, Bozorgzadeh A.
    Transplant Proc; 2005 Sep 05; 37(7):3182-6. PubMed ID: 16213344
    [Abstract] [Full Text] [Related]

  • 14. Cytomegalovirus disease in lung transplantation: impact of recipient seropositivity and duration of antiviral prophylaxis.
    Hammond SP, Martin ST, Roberts K, Gabardi S, Fuhlbrigge AL, Camp PC, Goldberg HJ, Marty FM, Baden LR.
    Transpl Infect Dis; 2013 Apr 05; 15(2):163-70. PubMed ID: 23230972
    [Abstract] [Full Text] [Related]

  • 15. Increased risk of breakthrough infection among cytomegalovirus donor-positive/recipient-negative kidney transplant recipients receiving lower-dose valganciclovir prophylaxis.
    Stevens DR, Sawinski D, Blumberg E, Galanakis N, Bloom RD, Trofe-Clark J.
    Transpl Infect Dis; 2015 Apr 05; 17(2):163-73. PubMed ID: 25661673
    [Abstract] [Full Text] [Related]

  • 16. Reassessing the impact of cytomegalovirus infection in kidney and kidney-pancreas transplantation.
    Becker BN, Becker YT, Leverson GE, Simmons WD, Sollinger HW, Pirsch JD.
    Am J Kidney Dis; 2002 May 05; 39(5):1088-95. PubMed ID: 11979354
    [Abstract] [Full Text] [Related]

  • 17. Emergence of drug-resistant cytomegalovirus in the era of valganciclovir prophylaxis: therapeutic implications and outcomes.
    Eid AJ, Arthurs SK, Deziel PJ, Wilhelm MP, Razonable RR.
    Clin Transplant; 2008 May 05; 22(2):162-70. PubMed ID: 18339135
    [Abstract] [Full Text] [Related]

  • 18. Clinical significance of post-prophylaxis cytomegalovirus infection in lung transplant recipients.
    Jaamei N, Koutsokera A, Pasquier J, Mombelli M, Meylan P, Pascual M, Aubert JD, Manuel O.
    Transpl Infect Dis; 2018 Aug 05; 20(4):e12893. PubMed ID: 29603543
    [Abstract] [Full Text] [Related]

  • 19. Impact of valganciclovir prophylaxis on the development of severe late-cytomegalovirus disease in high-risk solid organ transplant recipients.
    Cervera C, Pineda M, Linares L, Marcos MA, Esteva C, Antón A, Cofán F, Ricart MJ, Navasa M, Pérez-Villa F, Pumarola T, Moreno A.
    Transplant Proc; 2007 Sep 05; 39(7):2228-30. PubMed ID: 17889146
    [Abstract] [Full Text] [Related]

  • 20. High risk of cytomegalovirus infection following solid organ transplantation despite prophylactic therapy.
    Harvala H, Stewart C, Muller K, Burns S, Marson L, MacGilchrist A, Johannessen I.
    J Med Virol; 2013 May 05; 85(5):893-8. PubMed ID: 23508914
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.